CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Linda Wittkop1,2*, Julie Arsandaux1, Ana Trevino3, Maarten Schim van der Loeff4, Jane Anderson5, Ard van Sighem6, Jürg Böni7, Françoise Brun-Vezinet8, Vicente Soriano9, Faroudy Boufassa10, Norbert Brockmeyer11, Alexandra Calmy12, François Dabis12, Inna Jarrin13, Maria Dorrucci14, Vitor Duque15, Gerd Fätkenheuer16, Robert Zangerlé17, Elena Ferrer18, Kholoud Porter19, Ali Judd19, Nikolaos V. Sipsas20, Olivier Lambotte21, Leah Shepherd22, Catherine Leport23, Charles Morrison24, Cristina Mussini25, Niels Obel26, Jean Ruelle27, Carolyne Schwarze-Zander28, Anders Sonnerborg29, Ramon Teira30, Emilia Valadas32, Celine Colin2, Nina Friis-Møller33, Dominique Costagliola34, Rodolphe Thiebaut1,2,35, Geneviève Chene1,2† and Sophie Matheron36–38† on behalf of the COHERE in EuroCoord and ACHIEV2e Study Group†

1Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France; 2CHU de Bordeaux, Pôle de santé publique, F-33000 Bordeaux, France; 3Infectious Diseases Department, Hospital Carlos III, Madrid, Spain; 4GGD Amsterdam, Amsterdam, The Netherlands and CINIMA, AMC, Amsterdam, The Netherlands; 5Homerton University Hospital NHS Trust, London, UK; 6Stichting HIV Monitoring, Amsterdam, The Netherlands; 7Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland; 8Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris 7, Paris, France; 9Department of Infectious Diseases, Hospital Carlos III, Sinesio Delgado 10, Madrid 28029, Spain; 10Inserm U1018, CESP Centre for Research in Epidemiology and Population Health, Epidemiology of HIV and STI Team, Le Kremlin-Bicêtre, France and Univ Paris-Sud, Le Kremlin-Bicêtre, France; 11Department of Dermatology, Ruhr-University Bochum, Bochum, Germany; 12Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland; 13Red de Investigación en Sida, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Avda. Monforte de Lemos, Madrid 528029, Spain and CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; 14Istituto Superiore di Sanità, Rome, Italy; 15Hospital da Universidade de Coimbra, Departamento de Doenças Infecciosas, Coimbra, Portugal; 16First Department of Internal Medicine, University of Cologne, Cologne, Germany; 17Department of Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria; 18HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L’Hôpital de Llobregat Barcelona, Spain; 19Medical Research Council Clinical Trials Unit, University College London, London, UK; 20Pathophysiology Department, Laiko General Hospital and Medical School, National and Kapodistrian University of Athens, Athens, Greece; 21AP-HP Service de Médecine Interne, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France; 22Department of Infection and Population Health, University College London Medical School, London NW3 2PF, UK; 23Universite Paris Diderot, Sorbonne Paris Cité, UMR 1137, Paris, France and INSERM, UMR 1137, Paris, France; 24FHI 360, Durham, NC, USA; 25Clinic of Infectious Diseases, Department of Internal Medicine and Medical Specialities, University of Modena and Reggio Emilia, Modena, Italy; 26Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark; 27Université catholique de Louvain, IREC, AIDS Reference Laboratory, Brussels, Belgium; 28Department of Internal Medicine J, Bonn University Hospital, Bonn, Germany; 29Department of Infectious Diseases, Karolinska Institute, Stockholm, Sweden; 30Hospital Sierrallana, Torrelavega, Spain; 31Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University ‘Magna Graecia’, Catanzaro, Italy; 32Clinica Universitaria de Doenças Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; 33CHIP, Department of Infectious Diseases and Rheumatology, 2100 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark; 34Sorbonne Universités, UPMC Univ. Paris 06, UMR S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, F-75013 Paris, France and INSERM, UMR S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, F-75013 Paris, France; 35INRIA SISTM, F-33405 Talence, France; 36Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France; 37IAME, INSERM UMR 1137, Paris, France; 38Université Paris Diderot, Sorbonne Paris Cité, Paris, France

*Corresponding author. Tel: +33-(0)5-57-57-45-26; Fax: +33-(0)5-56-24-00-81; Linda.Wittkop@isped.u-bordeaux2.fr
†Equal contribution.
‡Members are listed in the Acknowledgements section.

Received 17 January 2017; returned 28 February 2017; revised 22 May 2017; accepted 30 May 2017
Beginning: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).

Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIEVe2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.

Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36–52) and 37 years (IQR 31–44), respectively. Median observed pretreatment CD4 cell counts/mm^3 were 203 (95% CI 100–290) in HIV-2+ patients and 223 (95% CI 100–353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were -105 (95% CI 77–134) in HIV-2+ patients and +202 (95% CI 199–205) in HIV-1+ patients, an observed difference of 97 cells/mm^3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm^3/year lower (95% CI 5–44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.

Conclusions: A poorer CD4 cell increase during first-line CART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.

Introduction

HIV-2 is less prevalent than HIV-1 and HIV-2+ individuals live mainly in West Africa, followed by Angola, Mozambique and Europe (primarily Portugal and France). HIV-2 infection is characterized by a lower plasma viral load (pVL) and a slower clinical progression. ART options for HIV-2 are restricted due to its natural resistance to NNRTIs and fusion inhibitors, and because some PIs have shown lower efficacy.

The 2013 WHO guidelines for treatment of HIV-2 infection recommended either triple NRTIs or two NRTIs combined with a ritonavir-boosted PI (PI/r) as first-line combination ART (cART), with a lapinavir-containing regimen as preferred option. In Europe, the recommended first-line cART regimen for HIV-2 infection consisted of two NRTIs and one PI or one PI/r since 2010. Of note, performing a randomized clinical trial designed to inform about optimal cART strategies for HIV-2 therapy is not feasible in Europe due to the low prevalence of HIV-2 infection, but is ongoing in West Africa.

CD4 cell recovery in HIV-2+ patients receiving first-line cART has been reported to be lower and slower than in HIV-1+ patients. Two observational studies have reported a better immunological response in HIV-2+ patients with a PI/r-based regimen compared with a triple NRTI regimen. Comparative studies between HIV-1 and HIV-2 are often hampered by the small number of patients infected with HIV-2 under similar standardized follow-up. Contradictory results regarding CD4 cell recovery have been reported when pretreatment pVL was taken into account. The lower replication rate of HIV-2 has been hypothesized as one possible explanation, leading to a poorer CD4 response to therapy. We compared immunological outcome in HIV-2+ and HIV-1+ patients under standard follow-up in Europe, by adjusting for pretreatment pVL levels at initiation of first cART, and other potential confounders.

Methods

Data collection

COHERE (HIV-1+ patients) and ACHIEVe2e (HIV-2+ patients) are prospective, multinational, observational cohort collaborations. Data were pooled in the COHERE in EuroCoord 2011 and ACHIEVe2e 2011 data merger. COHERE is a collaboration of 40 cohorts from across Europe and is part of the EuroCoord network (www.EuroCoord.net). The 23 cohorts participating in the present study through the COHERE network and the 9 cohorts participating through the ACHIEVe2e network (listed in the Acknowledgements section) submitted a defined dataset (patient demographics, current cART, CD4 counts and HIV RNA values, clinical status and events) to their network-specific Coordination Centre, using the HIV Cohort Data Exchange Protocol (HICDEP). The final data set was merged at the Bordeaux Regional Coordinating Centre for COHERE and ACHIEVe2e, adhering to strict quality-assurance guidelines and performing data quality checks.

Study population

Adult patients aged ≥18 years infected with either HIV-2 or HIV-1 (dual-seropositive and dual-infected patients were excluded) who started first-line cART regimen from 1997 to 2011 were included in the analysis. HIV-2+ and HIV-1+ patients receiving an NNRTI- or fusion inhibitor-containing regimen were not included because of the natural resistance of HIV-2 to these drug classes. Observations were excluded if patients presented without one pretreatment CD4 cell count in a window of 6 months before start of cART and without a pretreatment pVL based on quantification methods with a detection limit of ≤500 copies/mL. We used a cut-off of 500 copies/mL (2.7 log_{10} copies/mL) to define undetectable pVL, as a consensus shared by the majority of contributing centres in the dataset. Only patients with complete data for potential confounders (listed below) were included in all analyses (Figure S1, available as Supplementary data at JAC Online). Criteria used to initiate therapy of HIV-2 infection were those fitting the national treatment guidelines of each contributing centre effective at the time of cART start. The choice of antiretroviral combination was at the physician’s discretion based on these treatment guidelines.
Follow-up began at initiation of the first cART regimen (baseline). Follow-up was censored when the ART combination was modified for whatever reason, at death or at the last available CD4 cell counts, whichever occurred first.

**Virological data and CD4 cell count**

All serological results, pVL values and CD4 cell counts were obtained from laboratories of participating centres. HIV-1 and HIV-2 infections were diagnosed by ELISA tests confirmed by western blot. Quantification of HIV-2 viral load was assessed by in-house methods; the quality control assessments of quantification assays used by the ACHIeV2e network showed heterogeneity, which improved from 2006 to 2011. Pretreatment pVL and pretreatment CD4 cell counts were defined as the closest measurement in a window of 6 months before cART start.

**Statistical analysis**

We studied the effect of the HIV type on CD4 cell count at initiation of first cART (intercept) and on CD4 cell count change (cells/mm³/year) (slope) using linear mixed effect models with a random intercept and a random slope. The correlation between individual baseline CD4 value(s) and the subsequent CD4 slope(s) was handled through an unstructured covariance matrix of random effects. We checked the underlying model assumptions (normality and homoscedasticity of residuals).

We studied the effect of the following *a priori*-defined covariables on CD4 cell count at cART initiation and on CD4 cell count change by introducing an interaction term with the slope: HIV type (HIV-2 versus HIV-1, the main exposure variable), pVL as a continuous covariable (log_{10} copies/mL with imputation of the limit of detection for undetectable pVL), age (per 10-year increase), sex, geographical origin (Europe, Africa, Asia, other/unknown), HIV transmission route (heterosexual, homosexual, drug use, other/unknown), prior AIDS diagnosis, cART regimen (two NRTIs plus one ritonavir-boosted PI (other than lopinavir/ritonavir and darunavir/ritonavir), two NRTIs plus lopinavir/ritonavir or darunavir/ritonavir, three NRTIs, other ART combinations (mainly two or three NRTIs plus an unboosted PI or combinations with integrase inhibitors), period of cART initiation (1998–99, 2000–01, 2002–03, 2004–05, 2006–07, 2008–09, 2010–11) and time between HIV diagnosis and cART start. The slope was additionally adjusted for pretreatment CD4 cell count (per 100 cells/mm³ increase).

For all stratified or subgroup analyses described below we used the linear mixed regression models adjusted for the same covariables described above. Our main hypothesis was related to the potential for differences in pVL that might explain the differences in CD4 cell count evolution between HIV-2+ and HIV-1+ patients. To explore the stability of estimations, we further restricted the analysis to patients with a baseline pVL measured by a test with a limit of <100 copies/mL. We explored whether the effect of the virus type (HIV-2 or HIV-1) on CD4 cell response was modified by the level of baseline pVL by testing homogeneity of the association between HIV type and CD4 cell count evolution across baseline pVL strata (pVL <500 and ≥500 copies/mL) by integrating an interaction term in the linear mixed model.

We stratified the analyses of immunological response according to the type of cART received, i.e. three NRTIs, two NRTIs combined with a ritonavir-boosted PI (other than lopinavir/ritonavir and darunavir/ritonavir), and two NRTIs combined with either lopinavir/ritonavir or darunavir/ritonavir, to assess whether the cART regimen had an effect on the association between HIV type and CD4 cell response by testing homogeneity of the association of HIV type and CD4 cell count evolution across baseline cART regimen. The three categories of cART were chosen because these cART regimens were those recommended by WHO during the study period.

Results are presented for 12 months of follow-up after cART initiation but analyses are based on all available CD4 cell counts after cART initiation up to 115 and 150 months in HIV-2+ and HIV-1+ patients. We described categorical variables with frequencies (%) and continuous variables with medians (IQR). CD4 cell count changes were described with means and 95% CI after having assessed the normality assumption. Categorical variables were compared between HIV-2+ and HIV-1+ (included and excluded) patients using χ² tests or Fisher’s exact test as appropriate. Quantitative variables were compared between groups using the Wilcoxon–Mann–Whitney test.

All analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA).

**Results**

**Characteristics at cART start**

In the ACHIeV2e dataset 243 HIV-2+ patients fulfilled inclusion criteria; 58 of these were excluded, giving a total of 185 HIV-2+ patients in the analyses (Figure S1). We observed no significant difference between included and excluded HIV-2+ patients (Table S1). In the COHERE dataset 66483 HIV-1+ patients fulfilled inclusion criteria; 36162 of these were excluded, giving a total of 30231 HIV-1+ patients in the analyses (Figure S1). Included HIV-1+ patients were less often of European origin, were less often injection drug users, and were more often treated with two NRTIs combined with either lapinavir/ritonavir or darunavir/ritonavir compared with non-included patients (Table S1).

Baseline characteristics are presented in Table 1. At start of first-line cART, HIV-2+ patients were significantly older [median age 46 years (IQR 36–52)] compared with HIV-1+ patients [median age 37 years (32–44)] (P < 0.0001). The proportion of HIV-2+ patients with a pVL <500 copies/mL was significantly higher compared with patients infected with HIV-1 (60% versus 12%; P < 0.0001). Median pVL (IQR) was 3.2 log_{10} copies/mL (2.2–4.2) and 4.8 log_{10} copies/mL (4.0–5.4) in HIV-2+ and HIV-1+ patients, respectively. Median time between HIV diagnosis and cART start was significantly longer in HIV-2+ compared with HIV-1+ patients (1.0 versus 0.6 years; P = 0.0390). Two NRTIs plus lapinavir/ritonavir or darunavir/ritonavir was the most frequent cART regimen in HIV-2+ and HIV-1+ patients (43% and 36.5%, respectively) followed by two NRTIs plus other boosted PIs (23.8% versus 22.6%). Three NRTIs were prescribed in 13% and 7.2% of HIV-2+ and HIV-1+ patients, respectively. Median pretreatment CD4 cell count was similar in HIV-2+ versus HIV-1+ patients [203 cells/mm³ (IQR 100–290) versus 223 cells/mm³ (IQR 100–353); P = 0.1480]. After adjustment for a *a priori*-defined confounding covariables a significant difference in CD4 cell count at cART initiation remained between HIV-2+ and HIV-1+ patients. HIV-2+ patients had 56 CD4 cells/mm³ less at cART initiation compared with HIV-1+ patients (P < 0.0001).

**Follow-up data**

Median follow-up from first-line cART start until treatment modification, death or last available CD4 cell count was 10 months (IQR 1–27) and 8 months (IQR 2–21) in HIV-2+ and HIV-1+ patients, respectively (P = 0.0412). A median of 3 (IQR 2–8) and 4 (IQR 2–8) CD4 cell counts per HIV-2+ and HIV-1+ patient were available, respectively (P = 0.1555). Among HIV-2+ and HIV-1+ patients, 4.3% and 5.4% were lost to follow-up (P = 0.5017) and 1.1% and 1.7% died (P = 0.5344), respectively.

**CD4 cell count evolution**

In patients still followed at 12 months, median observed CD4 cell counts at 12 months were 265 cells/mm³ (IQR 182–420) in...
HIV-2+ and 404 cells/mm³ (IQR 262–571) in HIV-1+ patients (Figure 1). The mean observed change in CD4 cell count from start of cART to month 12 was +105 (95% CI 77–134) in HIV-2+ and +202 (95% CI 199–205) in HIV-1+ patients, which is an observed difference of 97 CD4 cells/mm³ in CD4 cell increase in 1 year.

After adjusting for pretreatment pVL only, the mean CD4 cell count increase remained significantly lower in HIV-2+ compared with HIV-1+ patients [difference of −41 CD4 cells/mm³/year (95% CI −61 to −20); P < 0.0001]. This difference persisted [difference of −25 CD4 cells/mm³/year (95% CI −44 to −5); P = 0.0127] after adjustment for pretreatment pVL and the other potential confounders (Table 2). All a priori-defined covariates were significantly and independently associated with CD4 cell count change. Of note, irrespective of the HIV type and all other variables included in the model, patients receiving three NRTIs had on average a significantly lower CD4 cell increase when compared with patients receiving a boosted PI-based cART regimen [difference in slope of −34 cells/mm³/year (95% CI −40 to −26); P < 0.0001; Table 2].

All subgroup and stratified analyses showed stable results. When considering only patients with a baseline pVL measured by an assay with a detection limit of <200 copies/mL (HIV-1 n = 27594; HIV-2 n = 129), CD4 cell increase was lower in HIV-2+ patients in adjusted analysis [difference of −29 CD4 cells/mm³/year (95% CI −44 to −5); P = 0.0227]. The effect of HIV type on CD4 cell count response was not modified by baseline pVL; thus, the effect of HIV on CD4 cell count response did not differ in those with a baseline pVL of <500 copies/mL (HIV-1 n = 26602; HIV-2 n = 75) and those with a baseline pVL <500 copies/mL (HIV-1 n = 3719; HIV-2 n = 110).

### Table 1. Characteristics of patients at initiation of first cART

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>HIV-1 (N = 30231)</th>
<th>HIV-2 (N = 185)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>37 (31–44)</td>
<td>46 (36–52)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>8179 (27.1)</td>
<td>88 (47.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Region of origin, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Europe</td>
<td>16517 (54.6)</td>
<td>47 (25.4)</td>
<td></td>
</tr>
<tr>
<td>Africa</td>
<td>2495 (8.3)</td>
<td>130 (70.3)</td>
<td></td>
</tr>
<tr>
<td>Asia</td>
<td>413 (1.4)</td>
<td>2 (1.1)</td>
<td></td>
</tr>
<tr>
<td>unknown/other</td>
<td>10806 (35.7)</td>
<td>6 (3.2)</td>
<td></td>
</tr>
<tr>
<td>Transmission risk group, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>heterosexual</td>
<td>10783 (35.7)</td>
<td>154 (83.2)</td>
<td></td>
</tr>
<tr>
<td>homo/bisexual male</td>
<td>11825 (39.1)</td>
<td>7 (3.8)</td>
<td></td>
</tr>
<tr>
<td>injecting drug user</td>
<td>4887 (16.2)</td>
<td>2 (1.1)</td>
<td></td>
</tr>
<tr>
<td>mother-to-child</td>
<td>26 (0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>unknown/other</td>
<td>2710 (9.0)</td>
<td>22 (11.9)</td>
<td></td>
</tr>
<tr>
<td>Prior AIDS diagnosis, n (%)</td>
<td>7169 (23.7)</td>
<td>42 (22.7)</td>
<td>0.7471</td>
</tr>
<tr>
<td>First-line cART regimen, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0002</td>
</tr>
<tr>
<td>2 NRTIs + 1 PI/RTV (not LPV or DRV)</td>
<td>6823 (22.6)</td>
<td>44 (23.8)</td>
<td></td>
</tr>
<tr>
<td>2 NRTIs + LPV/RTV or DRV/RTV</td>
<td>11039 (36.5)</td>
<td>79 (42.7)</td>
<td></td>
</tr>
<tr>
<td>3 NRTIs</td>
<td>2180 (7.2)</td>
<td>24 (13)</td>
<td></td>
</tr>
<tr>
<td>other regimens</td>
<td>10189 (33.7)</td>
<td>38 (20.5)</td>
<td></td>
</tr>
<tr>
<td>Period of treatment initiation, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>1998–99</td>
<td>6292 (20.8)</td>
<td>13 (7.0)</td>
<td></td>
</tr>
<tr>
<td>2000–01</td>
<td>3708 (12.3)</td>
<td>19 (10.3)</td>
<td></td>
</tr>
<tr>
<td>2002–03</td>
<td>3810 (12.6)</td>
<td>32 (173)</td>
<td></td>
</tr>
<tr>
<td>2004–05</td>
<td>4613 (15.3)</td>
<td>34 (18.4)</td>
<td></td>
</tr>
<tr>
<td>2006–07</td>
<td>5557 (18.4)</td>
<td>44 (23.8)</td>
<td></td>
</tr>
<tr>
<td>2008–09</td>
<td>5102 (16.9)</td>
<td>30 (16.2)</td>
<td></td>
</tr>
<tr>
<td>2010–11</td>
<td>1149 (3.8)</td>
<td>13 (7.0)</td>
<td></td>
</tr>
<tr>
<td>Pretreatment HIV RNA viral load, &lt;500 copies/mL, n (%)</td>
<td>3719 (12.3)</td>
<td>110 (59.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>log10 copies/mL, median (IQR)</td>
<td>4.8 (4.0–5.4)</td>
<td>3.2 (2.2–4.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Pretreatment CD4 cell count (cells/mm³), median (IQR)</td>
<td>223 (100–353)</td>
<td>203 (100–290)</td>
<td>0.1480</td>
</tr>
<tr>
<td>Delay between first HIV seropositivity and cART start (years), median (IQR)</td>
<td>0.61 (0.11–3.79)</td>
<td>0.97 (0.21–5.25)</td>
<td>0.0390</td>
</tr>
</tbody>
</table>

DRV, darunavir; LPV, lopinavir; RTV, ritonavir (boost).

*HIV-1: for 9462 patients the geographical origin was reported as unknown and 1344 were from other regions (Oceania-not Australia, Australia and New Zealand, America, North America, Central and South America and Middle East). HIV-2: for two patients the geographical origin was reported as unknown, two patients were from America and two patients were from Central and South America.

*Other regimens largely consisted of two or three NRTIs plus an unboosted PI or of combinations with integrase inhibitors [347 (1.1%) HIV-1-infected and 7 HIV-2-infected (3.8%) patients were treated with an integrase inhibitor].

*For patients with a viral load below the detection limit of the test, the detection limit has been imputed for the calculation.
25 cells/mm³/year). Furthermore, the difference between HIV-2 cART regimen and other main confounders (i.e. difference of remained significant after adjusting for pretreatment pVL, CD4 cell count increase between HIV-2 and HIV-1 was not modified by the cART regimen. 

In CD4 cell count response to first-line cART in HIV-2- and HIV-1-infected patients after adjustment for pretreatment CD4 cell counts. Of note, median CD4 cell count was 203 cells/mm³ in HIV-2 patients, similar to that reported at ART start in the IeDEA-West Africa HIV-2 cohort study (i.e. 166 cells/mm³). It has since been demonstrated that earlier treatment of HIV-1 infection is the best strategy for successful immune restoration. Long-term non-progressors account for 6% of the whole asymptomatic HIV-2 population, applying the same methodology as used to determine their proportion in HIV-1-infected patients. Among the remaining 94% there are patients with slightly progressive infection, who might benefit from earlier treatment leading to a better immune restoration.

We found an overall significantly lower CD4 cell increase in patients receiving a three-NRTI regimen compared with those receiving a ritonavir-boosted PI-based regimen. These findings obviously confirm the results of a European observational study that included some of the same HIV-2-infected patients, but also those of a recent West African study. Direct comparisons of different treatment regimens in observational studies are challenging and the gold standard design for such analyses and for evidence-based conclusions are randomized clinical trials. Such trials are not realizable in Europe due to the restricted number of potentially eligible HIV-2-infected patients living there. However, we report for the first time a comparison of CD4 cell response to first-line cART in a large population of HIV-2- and HIV-1-infected patients under standardized routine follow-up in Europe, allowing us to adjust the comparison for initial pVL levels, cART regimen, region of origin and other patient characteristics, such as pretreatment CD4 cell count and previous AIDS diagnosis, and for calendar periods of ART initiation.

Chronic immune activation and inflammation markers have been linked to disease progression in HIV-1 and HIV-2 patients. Differences in CD4 cell count response to first-line cART may be linked to differences in the underlying pathogenicity of these two viruses regarding immune activation. However, chronic immune activation is directly linked to pVL and in our comparison of immune response we controlled for pVL in various ways. Of note, it has been shown that HIV-2 non-progression is associated with better immune response to the virus, less immune activation and broad neutralizing antibody response; nevertheless, we do not know what came first: the particularities of HIV-2 replication or the immune response.

There are several limitations to our analyses. Differences in immunological outcome between HIV-1 and HIV-2 may have
Table 2. Estimated mean CD4 cell count differences at first-line cART start and CD4 cell count changes adjusted for all listed covariables

<table>
<thead>
<tr>
<th>Covariable</th>
<th>CD4 cell count at initiation of first cART (cells/mm³)</th>
<th>CD4 cell count change (cells/mm³/year)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean</td>
<td>95% CI</td>
</tr>
<tr>
<td>Intercept/slope</td>
<td>533</td>
<td>518–549</td>
</tr>
<tr>
<td>HIV type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-2 versus HIV-1</td>
<td>−56</td>
<td>−86 to −26</td>
</tr>
<tr>
<td>Pretreatment pVL (per additional 1 log₁₀ copies/mL)</td>
<td>−26</td>
<td>−28 to −24</td>
</tr>
<tr>
<td>Age at treatment initiation (per additional 10 years)</td>
<td>−22</td>
<td>−25 to −20</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>female versus male</td>
<td>26</td>
<td>19–32</td>
</tr>
<tr>
<td>Geographical origin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe (reference category)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Africa</td>
<td>−31</td>
<td>−40 to −22</td>
</tr>
<tr>
<td>Asia</td>
<td>−53</td>
<td>−73 to −33</td>
</tr>
<tr>
<td>unknown/other</td>
<td>−18</td>
<td>−23 to −13</td>
</tr>
<tr>
<td>Transmission group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>heterosexual (reference category)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>homo/bisexual male</td>
<td>53</td>
<td>47–59</td>
</tr>
<tr>
<td>injecting drug user</td>
<td>−25</td>
<td>−33 to −18</td>
</tr>
<tr>
<td>unknown/other</td>
<td>−9</td>
<td>−17 to 0</td>
</tr>
<tr>
<td>Prior AIDS diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>yes versus no</td>
<td>−126</td>
<td>−132 to −121</td>
</tr>
<tr>
<td>cART regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 NRTIs + 1 PI/RTV (reference category)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 NRTIs + LPV/RTV or DRV/RTV</td>
<td>−9</td>
<td>−15 to −3</td>
</tr>
<tr>
<td>3 NRTIs</td>
<td>53</td>
<td>42–63</td>
</tr>
<tr>
<td>other regimensa</td>
<td>24</td>
<td>17–32</td>
</tr>
<tr>
<td>Delay between first HIV seropositivity and cART start (per additional year)</td>
<td>−0.8</td>
<td>−1.4 to −0.3</td>
</tr>
<tr>
<td>Pretreatment CD4 cell count (per additional 100 cells/mm³)b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRV, darunavir; LPV, lopinavir; RTV, ritonavir (boost).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For CD4 cell count changes, a negative value indicates a lower CD4 increase and a positive value indicates a higher CD4 increase. N = 30231 for HIV-1-infected patients and N = 185 for HIV-2-infected patients.

Other regimens largely consisted of two or three NRTIs plus an unboosted PI or of combinations with integrase inhibitors.

The reported difference in CD4 cell count change is for a difference of 100 CD4 cells/mm³ at baseline, i.e. in a patient with 400 CD4 cells/mm³ the increase is of 2 cells less than compared with a patient with 300 CD4 cells/mm³.

been observed due to unmeasured confounding factors. We cannot completely rule out a selection bias as we did not analyse pretreatment slopes of CD4 cell decreases in HIV-1 and HIV-2 populations. We were unable to adjust for hepatitis B and/or for hepatitis C co-infection, although we adjusted for geographical origin and transmission risk group, which are closely linked to hepatitis B and C seroprevalences. Furthermore, follow-up was quite short and may hamper the extrapolation of our results to the long term.

Our study has several strengths. This is a large study comparing CD4 cell dynamics between HIV-2+ and HIV-1+ patients after start of first-line cART. The data quality was assured through two large European collaborative networks adhering to strict quality control checks, which allowed us to adjust our comparative analysis for the major confounding variables. Furthermore, we could confirm our main findings in subgroup and stratified analyses showing the robustness of the results and the absence of effect modification by initial pVL and cART regimen.
Differences in CD4 cell dynamics between HIV-2 and HIV-1 were consistent in all analyses, with a poorer CD4 cell increase after start of treatment in HIV-2+ patients, even after adjustment for pVL. Our results underline the need to identify other factors contributing to this lower CD4 cell response, such as more potent drugs against HIV-2, adapted to the particularities of the virus replication when compared with HIV-1, in order to improve case management.

Acknowledgements
We thank all the patients for participating in all these cohorts and the physicians, study nurses and laboratory researchers for their invaluable work.

Members of the COHERE in EuroCoord and ACHIEV2e Study Group

COHERE in EuroCoord

Steering Committee - Contributing Cohorts: Ali Judd (AALPHI), Robert Zangerle (AHLVOS), Giota Toulaumi (AMACS), Josphine Warszawski (ANRS C01 EPF/ANRS C011 OBSERVATOIRE EPF), Laurence Meyer (ANRS C02 SEROCO), François Dabis (ANRS C03 AQUITAINE), Murielle Mary Krause (ANRS C04 FIDH), Jade Ghosn (ANRS C06 PRIMO), Catherine Leport (ANRS C08 COPILOTE), Linda Wittkop (ANRS C013 HEPAVIH), Peter Reiss (ATHENA), Ferdinand Wit (ATHENA), Maria Pins (CASCADE), Heiner Bucher (CASCADE), Diana Gibb (CHIPS), Gerd Fütkenhuer (Cologne-Bonn), Julia Del Amo (CoRIS), Niels Obel (Danish HIV Cohort), Claire Thorne (ECS), Amanda Mocroft (EuroSIDA), Ole Kirk (EuroSIDA), Christoph Stephan (Frankfurt), Santiago Pérez-Hoyos (GEMES-Haemo), Osamah Hamouda (German ClinSurv), Barbara Bartmeyer (German ClinSurv), Nikoloz Chkhartishvili (Georgian National HIV/AIDS), Antoni Nogueruela- Julian (CORISPS-cat), Andrea Antinori (ICC), Antonella d’Arminio Monforte (ICONA), Norbert Brockmeyer (KOMPNET), Luis Prieto (Madrid PMTCT Cohort), Pablo Rojo Conejo (CORISPS-Madrid), Antoni Soriano-Monforte (ICONA), Anna Raposo (Iberia), Andrea Castagna (San Raffaele), Deborah Konopnick (St. Pierre Cohort), Tessa Goetghheu (St. Pierre Paediatric Cohort), Anders Sönnernor (Swedish InfCare), Carlo Torti (The Italian Master Cohort), Caroline Sabin (UK CHIC), Ramon Teira (VACH), Myriam Garrido (VACH), David Haerry (European AIDS Treatment Group).

Executive Committee: Stéphane de Wit (Chair, St. Pierre University Hospital, Paris), Jose Mª Miró (PISCIS), Dominique Costagliola (FIDH), Antonella d’Arminio-Monforte (ICONA), Antonella Castagna (San Raffaele), Julia del Amo (CoRIS), Amanda Mocroft (EuroSIDA), Dorthe Raben (Head, Copenhagen Regional Coordinating Centre), Geneviève Chène (Head, Bordeaux Regional Coordinating Centre). Paediatric Cohort Representatives: Ali Judd, Pablo Rojo Conejo.

Regional Coordinating Centres: Bordeaux RCC: Diana Barger, Christine Schwimmer, Monique Termote, Linda Wittkop; Copenhagen RCC: Maria Campbell, Casper M. Frederiksen, Nina Friis-Møller, Jesper Kjaer, Dorthe Raben, Rikke Salbøl Brandt.


The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694. A list of the funders of the participating cohorts can be found at www.COHERE.org.

ACHIEV2e

Clinical centres
France: Clinical centres from the ANRS COS HIV-2 Cohort: Bichat – Claude Bernard Hospital, Paris (Sophie Matheron); Riti-Salpêtrière Hospital, Paris (Roland Tubiana); Saint-Antoine Hospital, Paris (Marie-Caroline Meyohas); Cochin Hospital (Cornélia Bernasconi, Nicolas Dupin); Tenon Hospital, Paris (Laurence Slama); Saint-Louis Hospital, Paris (Diane Ponsarame, Caroline Lascoux-Combe, François-Julie Timsit); Delafontaine Hospital, Saint-Denis (Marie-Aude Khuong); L’Arboisière Hospital, Paris (Agathe Rami); Pau Brousse Hospital, Villejuif (Elena Teichner); Villeneuve Saint Georges Hospital (Caroline Semaille); Bicêtre Hospital, Le Kremlin-Bicêtre (Yann Quertainmont); Louis Mourier Hospital, Colombes (Martine Bloch); Logny Hospital, Marne la Vallée (Eric Foguel); Victor Dupuy Hospital, Argenteuil (Philippe Genet); Simone Veil Hospital, Eaubonne (Annie Leprêtre); Foch Hospital, Suresnes (David Zucman); Georges Pompidou Hospital, Paris (Marina Karmochkine); René Dubos Hospital, Pontoise (Laurent Blum); Gilles de la Citél Hospital, Corbeil Essonnes (Pierre Chevojon); Ambroise Paré Hospital, Boulogne Billancourt (Cyril Olivier); Robert Ballanger Hospital, Aulnay sous Bois (Jean-Luc Delassus); Montsouris Hospital, Paris (Loïc Bodard); Bégin Hospital, Saint Mandé (Patrick Imbert); Antoine Béclère Hospital, Clamart (François Bouët); Hôtel-Dieu Hospital, Nantes (Eric Billard); Saint-Jacques Hospital, Besançon (Christine Drobacheff-Thiébaut); Hôtel-Dieu Hospital, Lyon (Laurent Cotte); Pays d’Aix Hospital, Aix en Provence (Thierry Allègre); Côte de Nacre Hospital, Caen (Claude Bazin); Bretonneau Hospital, Tours (Pascale Nau); Charles Nicolle Hospital, Rouen (Yasmine Debad); Michallon Hospital, Grenoble (Pascale Leclercq); Pontchaillou Hospital, Rennes (Cédric Arricure); Intercommunal Hospital, Toulon-La Seyne sur Mer (Alain LaFauillade); Hôpital Pellegrin Hospital, Bordeaux (Jean-Marie Ragnaud, Hervé Dutronc); La Roche sur Yon Hospital (Philippe Perré); Cannes Hospital (Nathalie Montagne); Gue de Chaoulac Hospital, Montpellier (Jacques Reyes); Hôtel Dieu Hospital, Clermont Ferrand (Christiane Jacomet); Archet Hospital, Nice (Frédéric Sanderson); Civil Hospital, Strasbourg (David Rey); Saint André Hospital, Bordeaux (Maîté Longuy-Boursier); Angers Hospital (Jean-Marie Chennebault); Digne les Bains Hospital (Patricia Granet).

The Netherlands: The ATHENA database is maintained by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment.

Clinical centres
An asterisk denotes the site coordinating physician.


Wittkop et al.


Coordinating centre


Portugal: Clínico Universitario de Doenças Infecciosas, Lisboa (Francisco Antunes, Kamal Mansinho, Emilia Valadas).

CD4 cell count response to first-line cART in HIV-2+ versus HIV-1+ patients


Laboratories
Belgium: AIDS Reference Laboratory, Université Catholique de Louvain, AIDS Reference Laboratory, Brussels (Patrick Goubau, Jean Ruelle).
France: Cellular immunology laboratory, Pitie-Salpetrière Hospital, Paris (Brigitte Autran); virology laboratory, Bichat-Claude Bernard Hospital, Paris (Françoise Brun-Vezinet, Florence Damond, Diane Descamps), Saint-Louis Hospital, Paris (François Simon).
Italy: University of Milan, Department of Clinical Sciences ‘L. Sacco’ (Claudia Balotta).
Portugal: Hospital Egas Moniz, Lisbon (Ricardo Camacho, Perpetua Gomes); Clínica Universitária de Doenças Infecciosas e Parasitárias, Lisbon (Emilia Valadas); Centro Hospitalar e Universitário de Coimbra, Coimbra (Vitor Duque).
Spain: Laboratory of Molecular Biology, Infectious Diseases Department, Hospital Carlos III, Madrid (Ana Treviño & Vincent Soriano).
Switzerland: Laboratories of the Swiss HIV Cohort Study (resp. Jurg Böni, Fabrice Scheidegger, Nadia Schildknecht, Urs Widmer, Brussels (Patrick Goubau, Jean Ruelle).

Author contributions
None to declare.

Funding
The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under EuroCoord grant agreement number 260694. The funder has not played any decision-making role in the research.

Transparency declarations
None to declare.

Author contributions
G. C. and S. M. designed the study. L. W. and S. M. drafted the manuscript. Additionally, L. W. and J. A. were responsible for performing all analyses, act as guarantors for the analyses and have full access to the data set. All members of the COHERE in EuroCoord and ACHIeV2e Study Group participated in discussion on the design of the study, the choice of statistical analyses and interpretation of the findings, and were involved in the preparation and review of the final manuscript for submission.

Supplementary data
Figure S1 and Table S1 are available as Supplementary data at JAC Online.

References
21. Gottlieb GS, Sow PS, Hawes SE et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV)


27 Thiebaut R, Walker S. When it is better to estimate a slope with only one point. QJM 2008; 101: 821–4.


37 Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859–70.


